Cerus Past Earnings Performance
Past criteria checks 0/6
Cerus has been growing earnings at an average annual rate of 17.6%, while the Medical Equipment industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 17.9% per year.
Key information
17.6%
Earnings growth rate
22.9%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | 17.9% |
| Return on equity | -36.5% |
| Net Margin | -11.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Cerus Corporation (NASDAQ:CERS) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Sep 26
Analysts Are Upgrading Cerus Corporation (NASDAQ:CERS) After Its Latest Results
Aug 04Cerus Corporation's (NASDAQ:CERS) 30% Jump Shows Its Popularity With Investors
Jul 18Does Cerus (NASDAQ:CERS) Have A Healthy Balance Sheet?
Jul 12The Cerus Corporation (NASDAQ:CERS) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 05Here's Why Cerus (NASDAQ:CERS) Can Afford Some Debt
Apr 12Cerus Corporation (NASDAQ:CERS) Stock Rockets 29% But Many Are Still Ignoring The Company
Mar 07Slammed 29% Cerus Corporation (NASDAQ:CERS) Screens Well Here But There Might Be A Catch
Jan 18Health Check: How Prudently Does Cerus (NASDAQ:CERS) Use Debt?
Oct 06Is Cerus (NASDAQ:CERS) A Risky Investment?
Jul 07Slammed 32% Cerus Corporation (NASDAQ:CERS) Screens Well Here But There Might Be A Catch
May 12Cerus: Technical Support Fades, Investment Case Weakens (Technical Analysis)
Sep 29Cerus GAAP EPS of -$0.05 beats by $0.02, revenue of $47.63M beats by $4.87M
Aug 04Cerus: Lacks Conviction Against Macro Backdrop, Technicals Supportive Of Near-Term Upside
Jul 14Is Cerus (NASDAQ:CERS) Using Debt In A Risky Way?
Jul 06Is Cerus (NASDAQ:CERS) Using Debt Sensibly?
Mar 17Cerus Corporation: Outperforming And Gaining Momentum
Jan 28Revenue & Expenses Breakdown
How Cerus makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 176 | -20 | 74 | 58 |
| 30 Jun 24 | 170 | -24 | 72 | 61 |
| 31 Mar 24 | 164 | -32 | 74 | 65 |
| 31 Dec 23 | 156 | -37 | 76 | 68 |
| 30 Sep 23 | 154 | -50 | 81 | 72 |
| 30 Jun 23 | 153 | -51 | 85 | 71 |
| 31 Mar 23 | 156 | -46 | 84 | 67 |
| 31 Dec 22 | 162 | -43 | 83 | 64 |
| 30 Sep 22 | 158 | -38 | 82 | 61 |
| 30 Jun 22 | 154 | -42 | 83 | 60 |
| 31 Mar 22 | 145 | -49 | 83 | 62 |
| 31 Dec 21 | 131 | -54 | 81 | 63 |
| 30 Sep 21 | 119 | -60 | 78 | 65 |
| 30 Jun 21 | 107 | -61 | 74 | 66 |
| 31 Mar 21 | 97 | -61 | 70 | 64 |
| 31 Dec 20 | 92 | -60 | 67 | 64 |
| 30 Sep 20 | 85 | -62 | 65 | 64 |
| 30 Jun 20 | 79 | -66 | 65 | 64 |
| 31 Mar 20 | 76 | -69 | 66 | 63 |
| 31 Dec 19 | 75 | -71 | 66 | 60 |
| 30 Sep 19 | 70 | -71 | 64 | 56 |
| 30 Jun 19 | 68 | -67 | 62 | 51 |
| 31 Mar 19 | 65 | -62 | 59 | 47 |
| 31 Dec 18 | 61 | -58 | 57 | 43 |
| 30 Sep 18 | 61 | -53 | 55 | 38 |
| 30 Jun 18 | 56 | -52 | 53 | 35 |
| 31 Mar 18 | 50 | -56 | 53 | 34 |
| 31 Dec 17 | 44 | -61 | 53 | 34 |
| 30 Sep 17 | 37 | -63 | 52 | 35 |
| 30 Jun 17 | 37 | -64 | 52 | 34 |
| 31 Mar 17 | 37 | -65 | 51 | 34 |
| 31 Dec 16 | 37 | -63 | 49 | 31 |
| 30 Sep 16 | 37 | -64 | 48 | 30 |
| 30 Jun 16 | 35 | -65 | 46 | 30 |
| 31 Mar 16 | 34 | -63 | 46 | 27 |
| 31 Dec 15 | 34 | -56 | 46 | 26 |
| 30 Sep 15 | 34 | -61 | 45 | 24 |
| 30 Jun 15 | 36 | -56 | 43 | 23 |
| 31 Mar 15 | 36 | -48 | 41 | 23 |
| 31 Dec 14 | 36 | -39 | 38 | 22 |
| 30 Sep 14 | 36 | -24 | 34 | 21 |
| 30 Jun 14 | 36 | -34 | 33 | 18 |
| 31 Mar 14 | 38 | -33 | 31 | 17 |
| 31 Dec 13 | 40 | -43 | 30 | 15 |
Quality Earnings: CERS is currently unprofitable.
Growing Profit Margin: CERS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CERS is unprofitable, but has reduced losses over the past 5 years at a rate of 17.6% per year.
Accelerating Growth: Unable to compare CERS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CERS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (11.7%).
Return on Equity
High ROE: CERS has a negative Return on Equity (-36.45%), as it is currently unprofitable.